Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

69.32 +0.15 (+0.22%)
Official Closing Price Updated: 7:00 PM EDT, Jul 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
79 80 Next >
Market Briefing For Monday, Feb. 3, 2025
As to the market, at the moment it is being reactive to tariffs, news of which of course aborted the effort at finishing January on a strong note. It's that basic. 
Via Talk Markets
Topics Commodities Stocks / Equities World Trade
Top Picks For 2025: Skye Bioscience
Skye Bioscience is developing a peripheral restricted CB1 antibody to treat obesity by restoring leptin sensitivity and increasing fat metabolism, while avoiding the CB1-induced THC/neuro side effects.... 
Via Talk Markets
Topics Stocks / Equities
Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands
Via The Motley Fool
Want $1 Million in Retirement? 2 Stocks to Buy Now and Hold for Decades.
Via The Motley Fool
Investors should take notice of NYSE:NVO—it offers a great deal for the fundamentals it presents.
Take a closer look at NOVO-NORDISK A/S-SPONS ADR , a remarkable value stock. NYSE:NVO excels in fundamentals and maintains a very reasonable valuation. 
Via Chartmill
Market Whales and Their Recent Bets on NVO Options
Via Benzinga
$1000 Invested In Novo Nordisk 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Decoding Novo Nordisk's Options Activity: What's the Big Picture?
Via Benzinga
Will Medicare End Ozempic Maker Novo Nordisk's Obesity Drug Boom?
Via The Motley Fool
Billionaire Philippe Laffont Just Sold Top Artificial Intelligence Stocks Nvidia and AMD and Piled Into 2 Players Dominating Another High-Growth Billion-Dollar Industry
Via The Motley Fool
Topics Artificial Intelligence
RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders
Kennedy seeks to be Secretary of Health and Human Services — a position that would put him in charge of the health of the American people. 
Via Benzinga
Topics Government
5 Monster Stocks to Hold for the Next 10 Years
Most Wall Street professionals obsess over short-term returns. However, patient individual investors who buy and hold leading stocks on the cusp of new growth trends could strike it rich. 
Via The Motley Fool
Ozempic Receives FDA Approval To Treat Kidney Disease
The FDA on Tuesday approves Ozempic, the weight loss drug made by Novo Nordisk, for the treatment of chronic kidney disease in patients who also have type 2 diabetes. 
Via Benzinga
How Ozempic And Legal Weed Are Changing What America Eats
Ozempic curbs appetites, while cannabis legalization fuels munchies. Explore their public health impacts. 
Via Benzinga
Topics Cannabis
What Does the Future Hold for Eli Lilly?
Eli Lilly's two major GLP-1 drugs have dominated headlines, but a slate of new treatments in development—and some already available—suggest a bright future. 
Via MarketBeat
Veru Shares Tumble Despite Enobosarm's Lean Muscle Preservation Breakthrough
Veru's enobosarm showed significant body composition benefits in Phase 2b trials with semaglutide. Extension study results are due in April 2025. 
Via Benzinga
S&P 500 Slips From Intraday Highs As Investors Lock In Profits After A Strong Week
The S&P 500 ended lower on Friday after setting fresh intraday records earlier in the session, as investors took profits following a strong week. 
Via Talk Markets
Topics Stocks Stocks / Equities
Why Eli Lilly Stock Topped the Market Today
Via The Motley Fool
Stocks Stall, Gold Nears Record Highs As Dollar Faces Worst Week Since July 2023: What's Driving Markets Friday?
Wall Street paused for a breather on Friday, with the S&P 500 index hovering around the flatline at midday trading in New York after a five-day rally that pushed the market to fresh record highs this... 
Via Benzinga
Why Novo Nordisk Stock Jumped a Lucky 7.7% Today
Novo Nordisk may have found a winner in amycretin. 
Via The Motley Fool
Allurion Catapults 200% On Its Plans To Outdo Eli Lilly, Novo Nordisk
While the other companies are testing weight-loss drugs, Allurion has a different approach to obesity. 
Via Investor's Business Daily
Customers Bancorp, Twilio, Dana And Other Big Stocks Moving Higher On Friday
Via Benzinga
Novo Nordisk Stock Eyes Best Day In 17 Months On New Obesity Drug Trial Data: Retail Breathes Easy
The results also come as a relief following a selloff triggered by disappointing results from Novo’s CagriSema trial, which many deemed overblown. 
Via Stocktwits
Novo Nordisk Jumps On Experimental Weight-Loss Drug Trial Results
The Danish drug giant reported a 22% weight loss over 36 weeks. 
Via Investor's Business Daily
Novo Nordisk's Weekly Amycretin Delivers Up to 22% Weight Loss in Study, Stock Soars
Novo Nordisk's amycretin trial results highlight significant weight loss in adults with obesity, with further clinical development planned. 
Via Benzinga
3 Unstoppable Stocks to Buy That Wall Street Thinks Will Soar More Than 35%
Via The Motley Fool
Novo Nordisk Inks License Agreement For Sickle Cell Disease Candidate
IMMvention and Novo Nordisk form a partnership to co-develop oral therapies for sickle cell disease, focusing on BACH1 inhibitors with potential for other diseases. 
Via Benzinga
Ultrasound Weight Loss: GE HealthCare and Novo Nordisk’s Play
GLP-1 drugs have been all the rage for weight loss, but GE Healthcare and Novo Nordisk are working on a non-invasive approach to controlling metabolic functions 
Via MarketBeat
Investors should take note of NYSE:NVO, a growth stock that remains attractively priced.
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) is showing good growth, while it is not too expensive. 
Via Chartmill
Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
Eleven large-cap stocks were the worst performers in the last week. Short positions announced for FTAI, revenue updates for MRNA, and price forecasts changed for GME, SNAP, RKLB, NTRA, LLY, ICLR, BNTX,... 
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
79 80 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.